Department of Neurology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Brain Res. 2009 Dec 11;1305:64-73. doi: 10.1016/j.brainres.2009.09.098. Epub 2009 Oct 1.
Peroxisome proliferator-activated receptor gamma (PPARgamma) agonists play important roles in the regulation of energy metabolism and are widely used for patients with type 2 diabetes. PPARgamma agonists reportedly reduce plasma glucose levels by recruiting glucose transporters to the cellular membrane, resulting in the enhanced uptake of glucose. However, only a limited number of studies have examined the effect of PPARgamma on cerebral glucose metabolism. In the present study, we examined the effects of a PPARgamma agonist, pioglitazone, on glucose metabolism in cultured rat neurons and astroglia. Cultures of neurons or astroglia were prepared from Sprague-Dawley rats. The cells were treated with pioglitazone (0-50 muM) for 48 hours prior to assay. Lactate released into the culture medium (an index of glycolytic glucose metabolism) and [U-(14)C]lactate or [1-(14)C]pyruvate oxidation (an index of oxidative glucose metabolism) were measured. In addition, the production of cellular reactive oxygen species (ROS) was determined utilizing an H(2)DCFDA assay. Forty-eight hours of exposure to pioglitazone (0.5 and 5 muM) resulted in dose-dependent increases in lactate release into the astroglial culture medium but not into the neuronal culture medium. [U-(14)C]lactate oxidation and [1-(14)C]pyruvate oxidation were enhanced in the neurons, but not in the astroglia. These actions of pioglitazone were not inhibited by 2-chloro-5-nitrobenzanilide (GW9662), a potent antagonist of PPARgamma, and were not mimicked by N-(2-benzoylphenyl)-O-[2-(methyl-2-pyridinylamino)ethyl]-l-tyrosine (GW1929), a non-thiazolidinedione PPARgamma agonist. Pioglitazone enhanced aerobic glycolysis and lactate release in astroglia, while the oxidative metabolism of glucose, but not glycolysis, was augmented in neurons without increasing ROS production. These results indicate that pioglitazone may enhance the efficiency of glucose metabolism in the brain.
过氧化物酶体增殖物激活受体γ(PPARγ)激动剂在调节能量代谢中起着重要作用,广泛用于 2 型糖尿病患者。PPARγ 激动剂据报道通过将葡萄糖转运蛋白募集到细胞膜上来降低血糖水平,从而增强葡萄糖的摄取。然而,只有少数研究检查了 PPARγ 对大脑葡萄糖代谢的影响。在本研究中,我们研究了 PPARγ 激动剂吡格列酮对培养的大鼠神经元和星形胶质细胞葡萄糖代谢的影响。神经元或星形胶质细胞培养物从 Sprague-Dawley 大鼠中制备。在测定前,将细胞用吡格列酮(0-50 μM)处理 48 小时。测量培养上清液中释放的乳酸(糖酵解葡萄糖代谢的指标)和 [U-(14)C]乳酸或 [1-(14)C]丙酮酸氧化(氧化葡萄糖代谢的指标)。此外,利用 H(2)DCFDA 测定法测定细胞内活性氧物种(ROS)的产生。48 小时暴露于吡格列酮(0.5 和 5 μM)导致乳酸释放到星形胶质细胞培养基中的剂量依赖性增加,但不增加神经元培养基中的乳酸释放。[U-(14)C]乳酸氧化和 [1-(14)C]丙酮酸氧化在神经元中增强,但在星形胶质细胞中没有增强。吡格列酮的这些作用不受 2-氯-5-硝基苯甲酰胺(GW9662)的抑制,GW9662 是 PPARγ 的一种有效拮抗剂,也不受 N-(2-苯甲酰基苯基)-O-[2-(甲基-2-吡啶基氨基)乙基]-L-酪氨酸(GW1929)的模拟,GW1929 是一种非噻唑烷二酮类 PPARγ 激动剂。吡格列酮增强了星形胶质细胞的有氧糖酵解和乳酸释放,而葡萄糖的氧化代谢,而不是糖酵解,在不增加 ROS 产生的情况下增强了神经元。这些结果表明,吡格列酮可能提高大脑中葡萄糖代谢的效率。